Thrombogenicity of total parenteral nutrition solutions: II. Effect on induction of endothelial cell procoagulant activity

Wakefield, Andrew J.; Cohen, Zane; Rosenthal, A.; Craig, M.; Jeejeebhoy, K. N.; Gotlieb, A; Levy, G. A.

doi:10.1016/0016-5085(89)91693-4

Cited by 38 publications

(12 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have also shown that at higher concentrations (500 mg/1), phosphatidylcholine in creases the procoagulant activity of the mesothelial cells which may also be the reason of easier formation of intra peritoneal adhesions. A similar effect of phospholipids on the procoagulant activity of the endothelial cells was de scribed previously [14], This study suggests that intraperitoneal phosphati dylcholine may disturb the function of the mesothelial cells. However, most of the deleterious effects of phosphati dylcholine were observed at concentrations higher than those used in the dialysis fluid.…”

Section: Discussionsupporting

confidence: 53%

Effect of Phosphatidylcholine on the Function of Human Mesothelial Cells in vitro

Bręborowicz

Witowski

Knapowski

et al. 1993

Nephron

View full text Add to dashboard Cite

We tested the hypothesis that phosphatidylcholine (PC) molecules present in the dialysis solution may interact with the mesothelial cell membrane and modify its function. In vitro experiments were performed on human mesothelial cells (HMC) in culture. PC decreased proliferation of HMC when used at concentrations of 200 mg/l and higher. PC was also cytotoxic to HMC as measured by the release of lactate dehydrogenase from their cytosol. Cells exposed to PC had a diminished capacity for taking up ⁸⁶Rb from medium. PC decreased the fibrinolytic properties of HMC and increased their procoagulant activity. Our results suggest that the positive short-term effect of the addition of PC to the dialysis solution (i.e., an increase in ultrafiltration) may be over-shadowed by its deleterious action on HMC membrane.

show abstract

Section: Discussionsupporting

confidence: 53%

Effect of Phosphatidylcholine on the Function of Human Mesothelial Cells in vitro

Bręborowicz

Witowski

Knapowski

et al. 1993

Nephron

View full text Add to dashboard Cite

show abstract

“…444,[532][533][534][535][536][537][538] Two studies have reported the use of VKA primary prophylaxis in this group of patients. 444,535 However, VKA primary prophylaxis commonly is used for children receiving long-term home parenteral nutrition, despite the lack of similar practice in adults.…”

Section: Endovascular Stentsmentioning

confidence: 99%

Antithrombotic Therapy in Neonates and Children

Monagle

Chan

Goldenberg

et al. 2012

Chest

1,246

559

View full text Add to dashboard Cite

“…UVCs or CVLs are used extensively in premature and full term infants who require supportive care in the form of fluids, drugs or total parenteral nutrition (TPN). There are several possible mechanisms by which CVLs cause TEs including damage to vessel walls, 4 disrupted blood flow, infusion of substances such as total parenteral nutrition that damage endothelial cells, 5 and thrombogenic catheter materials. 6 …”

Section: Central Venous Line Related Thrombosismentioning

confidence: 99%

Thromboembolic Disease and Antithrombotic Therapy in Newborns

Andrew¹,

Monagle²,

deVeber³

et al. 2001

Hematology

View full text Add to dashboard Cite

This update uses an evidence based approach to analyze and present the epidemiology of neonatal thrombosis, etiologies, currently used techniques for diagnosis with their limitations, and current therapeutic approaches. In addition, the approaches to both prevention and optimal therapies are discussed.In Section I Dr. Paul Monagle addresses the epidemiology of neonatal thrombosis outside of the central nervous system in both arterial and venous locations, and those that occur in utero. The specific contributions of catheters and congenital prothrombotic disorders are delineated. Dr. Monagle also describes currently used techniques for the diagnosis of thrombotic events as well as their limitations and the current therapeutic approaches.In Section II, Dr. Gabrielle deVeber reviews the epidemiology of neonatal thrombosis within the central nervous system, in both arterial and venous locations and those that occur in utero. The neurological presentation, risk factors including congenital prothrombotic disorders, anatomical distribution, diagnostic tests, use of antithrombotic therapy and neurologic outcome of neonates with either sinovenous thrombosis or arterial ischemic stroke are discussed.In Section III, Dr. Anthony Chan reviews the current approaches to the prevention and treatment of neonatal thrombosis. Information on the differences in the response of neonates compared to adults to antithrombotic therapy and new approaches to the prevention and treatment of thrombosis in neonates are emphasized.Thromboembolic events (TEs) during childhood are increasing in their frequency and severity, and occur in children surviving previously life-threatening primary diseases. Newborns comprise the largest group of children developing TEs. This paper discusses the epidemiology, diagnostic tests, acquired and congenital prothrombotic risk factors, long-term outcomes, and antithrombotic therapy for the management of TEs in newborns. Due to the unique features and the significance of TEs in the central nervous system (CNS), sinovenous thrombosis (SVT) and arterial ischemic stroke (AIS) will be considered separately; cerebrovascular lesions in premature infants will not be discussed.In preparation for this manuscript, comprehensive Medline reviews were performed to identify all relevant publications, which were analyzed based upon the study design; results of studies with stronger designs were given more influence in the analysis. The striking features of this review were the deficiencies in our knowledge with respect to appropriate diagnostic strategies, optimal therapy for newborns with TEs, and the contribution of congenital prothrombotic disorders. Well-designed trials are required to improve our ability to care for neonates with TEs.

show abstract

Thrombogenicity of total parenteral nutrition solutions: II. Effect on induction of endothelial cell procoagulant activity

Cited by 38 publications

References 10 publications

Effect of Phosphatidylcholine on the Function of Human Mesothelial Cells in vitro

Effect of Phosphatidylcholine on the Function of Human Mesothelial Cells in vitro

Antithrombotic Therapy in Neonates and Children

Thromboembolic Disease and Antithrombotic Therapy in Newborns

Contact Info

Product

Resources

About